Harmony P. Garges MD MPH and Menassie Taddese MBA appointed to Medexus’s board of directors
Appointments bolster Medexus board’s clinical and economical knowledge, specifically in the United States
TORONTO and CHICAGO, Feb. 06, 2023 (World NEWSWIRE) — Medexus Prescription drugs (Medexus) (TSX: MDP) (OTCQX: MEDXF) is delighted to welcome Harmony P. Garges MD MPH, Main Clinical Officer of ViiV Health care, and Menassie Taddese MBA, former government at Pfizer and Viatris, to the Medexus board of administrators.
“We are pretty pleased to welcome Harmony and Menassie, two professional specialists whose competencies, experience, and abilities will serve to diversify and dietary supplement individuals of the present-day associates of our board,” commented Benoit Gravel, Chair of the Payment, Company Governance, and Nominating Committee of the Board of Directors.
Ken d’Entremont, Main Executive Officer of Medexus, included, “We are thrilled to have Harmony and Menassie sign up for our board. As we proceed to appraise new possibilities to mature our business, strengthening our crew continues to be a priority. Harmony’s important expertise major healthcare affairs and health-related regulatory matters and Menassie’s potent administration working experience and know-how in company finance will certainly be belongings as we develop our business enterprise organically and engage in new enterprise and corporate enhancement initiatives.”
Dr Garges and Mr Taddese were elected to fill two newly designed directorships with impact as of February 6, 2023 and will to begin with provide till the future annual meeting of Medexus shareholders. For more details about the Medexus board of directors, see the Governance portion of Medexus’s company site.
About Dr Garges and Mr Taddese
Harmony P. Garges MD MPH delivers 18 years of multinational pharmaceutical management encounter in the United States and the British isles to the Medexus board. Dr Garges has served as Main Clinical Officer of ViiV Healthcare due to the fact August 2019. In this role, Dr Garges is accountable for all factors of human protection and health care governance and for the worldwide healthcare affairs method and execution for the business. Dr Garges joined ViiV Health care in 2016 just after investing over a ten years at GSK in different management roles throughout R&D, pharmacovigilance, and health-related affairs. Through her profession, Dr Garges has delivered healthcare management for over a dozen new drug apps and new product or service launches.
Menassie Taddese MBA is a seasoned veteran of the biopharmaceutical market with broad ranging working experience in basic administration, finance, business enterprise transformation, partnership creation, and in general leadership. He provides around 26 years of working experience main big industrial and cross-purposeful companies across the world to the Medexus board.
About Medexus
Medexus is a chief in innovative and rare disorder cure alternatives with a strong North American commercial system and a portfolio of established very best-in-course goods. Our recent aim is on the therapeutic locations of hematology, automobile-immune conditions, and allergy. We go on to build a really differentiated company with a increasing portfolio of ground breaking and high-value orphan and unusual illness products and solutions that will underpin our development for the next 10 years.
Our current major items are IXINITY®, an intravenous recombinant factor IX therapeutic for use in people 12 years of age or older with Hemophilia B (a hereditary bleeding dysfunction characterized by a deficiency of clotting factor IX in the blood, which is needed to manage bleeding) Rasuvo® and Metoject®, a exceptional formulation of methotrexate (car-pen and pre-stuffed syringe) built to handle rheumatoid arthritis and other vehicle-immune health conditions Rupall®, an modern prescription allergy treatment with a one of a kind method of motion and Gleolan® (aminolevulinic acid hydrochloride or ALA HCl), an Fda-approved, orphan drug specified optical imaging agent now indicated in individuals with glioma (suspected Planet Well being Corporation Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue for the duration of operation.
We have also certified treosulfan, part of a preparative regimen for allogeneic hematopoietic stem mobile transplantation to be used in blend with fludarabine, for commercialization in the United States and Canada. Treosulfan was accepted by Health and fitness Canada in June 2021 and is promoted in Canada as Trecondyv™. Treosulfan is at the moment the issue of a regulatory overview procedure with the US Food and Drug Administration.
Our mission is to deliver the best health care solutions to healthcare industry experts and individuals. We strive to produce on this mission by performing on our core values: High quality, Innovation, Consumer Assistance, and Collaboration.
Contacts
For more information, make sure you make contact with any of the subsequent:
Medexus
Ken d’Entremont, Main Executive Officer
Medexus Prescribed drugs
Tel: 905-676-0003
E mail: [email protected]
Marcel Konrad, Chief Financial Officer
Medexus Pharmaceuticals
Tel: 312-548-3139
Electronic mail: [email protected]
Investor Relations
Victoria Rutherford
Adelaide Funds
Tel: 480-625-5772
Email: [email protected]
Ahead-wanting statements
Sure statements designed in this push launch contain forward-searching details within the which means of relevant securities laws (forward-searching statements). The words and phrases “anticipates”, “believes”, “expects”, “will”, “plans”, “potential”, and related words and phrases, phrases, or expressions are often supposed to detect forward-on the lookout statements, while not all forward-searching statements incorporate these pinpointing words and phrases, phrases, or expressions. Unique forward-wanting statements in this news launch contain, but are not limited to, statements with regards to Medexus’s business technique or outlook and long run growth strategies and the expected tenure and contributions of Medexus’s directors. These statements are primarily based on factors or assumptions that had been utilized in drawing a summary or generating a forecast or projection, which includes assumptions dependent on historical tendencies, present-day circumstances, and predicted long term developments. Considering that forward-wanting statements relate to foreseeable future gatherings and problems, by their really mother nature they have to have creating assumptions and include inherent risks and uncertainties. Medexus cautions that even though it is considered that the assumptions are fair in the instances, these challenges and uncertainties give increase to the possibility that true results may possibly vary materially from the expectations established out in the forward-on the lookout statements. Content chance factors incorporate, but are not confined to, those established out in Medexus’s elements filed with the Canadian securities regulatory authorities from time to time, like Medexus’s most the latest annual facts sort and management’s dialogue and examination. Offered these challenges, undue reliance really should not be put on these forward-on the lookout statements, which are made only as of the day of this information launch. Other than as specially necessary by law, Medexus undertakes no obligation to update any forward-wanting statements to reflect new facts, subsequent or normally.
link